Fig. 1.

Diabetic phenotypes in wild-type (WT) and cystic fibrosis (CF) transmembrane conductance regulator (CFTR) knockout (CFKO) mice. A: Increase in blood glucose levels in streptozotocin (STZ)-treated mice (n = 11–19). Under basal conditions, no significant differences between WT and CFKO mice were observed. 30 days after STZ treatments, blood glucose levels were significantly elevated in both WT and CFKO mice but were not significantly different between genotypes. B: changes in mouse weight 30 days after STZ treatment. STZ-treated animals showed a greater loss of body weight than untreated controls regardless of genotype (*P < 0.05; n = 22–31). No differences between non-STZ-treated WT and CFKO mice were observed. C: intraperitoneal glucose tolerance test. STZ-treated animals showed an exaggerated increase in blood glucose levels following intraperitoneal glucose administration where differences from baseline to peak glucose concentrations were greater (*P < 0.05; n = 3–5). Based on area-under-the-curve analyses, CFKO and WT mice treated with STZ were not statistically different, as both STZ-treated CFKO and WT mice produced similar glycemic profiles. No differences between non-STZ-treated WT and CFKO mice were observed.